For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Sodium valproate (NON childbearing potential) - Epilepsy
PAD Profile : Sodium valproate (NON childbearing potential) - Epilepsy
Traffic Light Status
Status 1 of 3.
- Crushable tablets
- Gastro-resistant tablets
- Modified release tablets
- Oral solution
- Tablets
Status 2 of 3.
- Capsules (slow release)
- Granules (slow release)
Status 3 of 3.
Guidelines
No guidelines returned.
Other Drugs
- Eslicarbazepine acetate
- Carbamazepine
- Clobazam
- Lacosamide
- Clonazepam
- Perampanel
- Ethosuximide
- Felbamate
- Rufinamide
- Gabapentin
- Stiripentol
- Lamotrigine
- Zonisamide
- Levetiracetam
- Oxcarbazepine
- Phenobarbital
- Piracetam
- Phenytoin
- Pregabalin
- Topiramate
- Brivaracetam
- Sodium valproate (with childbearing potential)
- Cannabis (medicinal)
- Vigabatrin
- Cenobamate
- Primidone
- Tiagabine
- Sulthiame
Other Indications
Additional Documents
Committee Recommendations
Three infographics have been produced to clarify in which situations review by two specialists may be required for patients who are prescribed valproate:
• for female patients under 55 years old
• for male patients under 55 years old
• for male and female patients 55 years and older
The Surrey Heartlands APC reviewed the Blue traffic light status for patients with epilepsy and WITHOUT child-bearing potential.
The Blue status remains with the expectation that treatment will be initiated and stabilised by a specialist and patients will receive a minimum of 1 month supply from the specialist before transfer of care.
No supplementary information sheet is required